Humacyte’s Vascular Trauma Treatment Receives Priority Review from FDA
Shares of Humacyte, a clinical-stage biotechnology company, surged after receiving priority review from the U.S. Food and Drug Administration (FDA) for its vascular trauma treatment. The stock experienced an almost…